Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19

NCT ID: NCT04753346

Last Updated: 2023-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-15

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

COVID-19 (Coronavirus disease 2019) is a new infectious disease caused by a virus named as SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2). Although it can have a devastating effect on many organs, the respiratory tract is particularly affected. In the course of the disease, a wide clinical spectrum is observed, from flu-like illness to lung failure. Some of the patients who survived the disease continue to have problems such as shortness of breath, fatigue, decrease in walking distance, decrease in participation in daily life activities. These problems suggest that the effects on respiratory and cardiac functions continue even after the disease ends. This study was designed to demonstrate the effects and extent of COVID-19 on cardiopulmonary capacity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aims of the research are that demonstrate change in cardiopulmonary fitness level in patients with COVID-19 according to normal values and reveal the relationship of this change with age, gender, physical activity level, disease severity and accompanying medical conditions.

Patients older than 18 years old who are diagnosed with COVID-19 according to clinical symptoms and rt-PCR test positivity and at least 30 days past the end of their symptoms are accepted for the study.

According to World Health Organization's (WHO) classification, COVID-19 disease severity is determined. Physical activity level of the patients before COVID-19 is evaluated with International Physical Activity Questionnaire. Risk of anxiety and depression of the patients is identified with Hospital Anxiety and Depression Scale (HADS), which has 14 questions. To evaluate cardiopulmonary fitness level, cardiopulmonary exercise test (CPET) and 6-minute walk test are applied. Cardiopulmonary exercise test is gold standard to determine cardiac and respiratory functions. Pulmonary function test is performed to identify the conditions that affect the results of cardiopulmonary exercise test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID 19

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cardiopulmonary exercise test Exercise capacity COVID 19 6 minute walk test

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mild Disease

Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.

Physical Activity Level

Intervention Type OTHER

International Physical Activity Questionnaire

Anxiety and Depression Assessment

Intervention Type OTHER

Hospital Anxiety and Depression Scale

Exercise Capacity

Intervention Type DIAGNOSTIC_TEST

6 Minute Walk Test

Pulmonary Function Test

Intervention Type DIAGNOSTIC_TEST

Spirometry

Cardiopulmonary Fitness Level

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary Exercise Test

Cognitive Assessment

Intervention Type OTHER

Montreal Cognitive Assessment

Pneumonia

Patients with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥ 90% on room air

Physical Activity Level

Intervention Type OTHER

International Physical Activity Questionnaire

Anxiety and Depression Assessment

Intervention Type OTHER

Hospital Anxiety and Depression Scale

Exercise Capacity

Intervention Type DIAGNOSTIC_TEST

6 Minute Walk Test

Pulmonary Function Test

Intervention Type DIAGNOSTIC_TEST

Spirometry

Cardiopulmonary Fitness Level

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary Exercise Test

Cognitive Assessment

Intervention Type OTHER

Montreal Cognitive Assessment

Severe Pneumonia

Patients with clinical signs of pneumonia (fever, cough, dyspnoea,fast breathing) plus one of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; or SpO2 \< 90% on room air.

Physical Activity Level

Intervention Type OTHER

International Physical Activity Questionnaire

Anxiety and Depression Assessment

Intervention Type OTHER

Hospital Anxiety and Depression Scale

Exercise Capacity

Intervention Type DIAGNOSTIC_TEST

6 Minute Walk Test

Pulmonary Function Test

Intervention Type DIAGNOSTIC_TEST

Spirometry

Cardiopulmonary Fitness Level

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary Exercise Test

Cognitive Assessment

Intervention Type OTHER

Montreal Cognitive Assessment

Critical Disease

Patients have one of the following: acute respiratory distress syndrome; sepsis; or septic shock.

Physical Activity Level

Intervention Type OTHER

International Physical Activity Questionnaire

Anxiety and Depression Assessment

Intervention Type OTHER

Hospital Anxiety and Depression Scale

Exercise Capacity

Intervention Type DIAGNOSTIC_TEST

6 Minute Walk Test

Pulmonary Function Test

Intervention Type DIAGNOSTIC_TEST

Spirometry

Cardiopulmonary Fitness Level

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary Exercise Test

Cognitive Assessment

Intervention Type OTHER

Montreal Cognitive Assessment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physical Activity Level

International Physical Activity Questionnaire

Intervention Type OTHER

Anxiety and Depression Assessment

Hospital Anxiety and Depression Scale

Intervention Type OTHER

Exercise Capacity

6 Minute Walk Test

Intervention Type DIAGNOSTIC_TEST

Pulmonary Function Test

Spirometry

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary Fitness Level

Cardiopulmonary Exercise Test

Intervention Type DIAGNOSTIC_TEST

Cognitive Assessment

Montreal Cognitive Assessment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of SARS-Cov2 with a positive result of reverse polymerase-transcriptase chain reaction test
* It must have been at least 30 days after symptoms of COVID-19 improved.

Exclusion Criteria

* 5 days after acute myocardial infarction
* Unstable angina
* Active endocarditis, myocarditis or pericarditis
* Symptomatic severe aortic stenosis
* Uncontrolled heart failure
* Acute pulmonary embolus, pulmonary infarction or thrombosis of lower extremities
* Suspected dissecting aneurysm
* Uncontrolled asthma
* Room air desaturation at rest (O2 ⩽85%)
* Respiratory failure
* Acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
* Mental impairment
* Severe untreated arterial hypertension at rest (\>200 mm Hg systolic, \>120 mm Hg diastolic)
* High-degree atrioventricular block
* Orthopaedic, neurological or systemic impairments that leading to inability to perform test
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Burak Kamil Turan

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ankara University, Faculty of Medicine, Physical Medicine and Rehabilitation Department

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Burak K Turan

Role: CONTACT

Phone: 90(312)5082822

Email: [email protected]

Yesim Aytür

Role: CONTACT

Phone: 90(312)5082822

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Burak K Turan

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

I11-670-20

Identifier Type: -

Identifier Source: org_study_id